Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

AstraZeneca Files NDA For Symbicort Asthma Therapy

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Company has discussed potential delays in review of the metered dose inhaler asthma product.

You may also be interested in...



FDA Approves Symbicort Asthma Combo Therapy

FDA approved AstraZeneca's asthma therapy Symbicort (budesonide/formoterol) July 21 for patients 12 and older after a standard 10-month review

FDA Approves Symbicort Asthma Combo Therapy

FDA approved AstraZeneca's asthma therapy Symbicort (budesonide/formoterol) July 21 for patients 12 and older after a standard 10-month review

Symbicort NDA On-Track Despite FDA Data Request, AstraZeneca Says

FDA has requested additional chemistry, manufacturing and control data for Symbicort inhalation delivery device. While AstraZeneca does not believe this will significantly delay product development, the company does have a back-up strategy for a slightly modified device.
Table

View full table

Related Content

Pink Sheet Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

PS062938

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By